- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05660473
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
March 1, 2023 updated by: Institute of Hematology & Blood Diseases Hospital
The pediatric-inspired regimen has greatly improved the prognosis of adult patients with with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph- ALL), but relapse remains a great challenge.
Venetoclax (Ven) is an oral, selective inhibitor of B-cell lymphoma 2 (Bcl-2).
Although this drug is currently used primarily for acute myeloid leukemia, in vitro as well as small cohort studies suggest a effect in acute lymphoblastic leukemia.
This study proposes to combine pediatric-inspired regimen with venetoclax for the treatment of adult patients with Ph- ALL, aiming to improve the MRD-negative complete remission rate measured by flow cytometry after induction and to reduce relapse, thus further improving patients overall survival.
Study Overview
Status
Recruiting
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tianjin, China, 300020
- Recruiting
- Institute of Hematology & Blood Diseases Hospital
-
Contact:
- Jianxiang Wang, Dr.
- Phone Number: 86-22-23909120
- Email: wangjx@medmail.com.cn
-
Principal Investigator:
- Jianxiang Wang, Dr.
-
Sub-Investigator:
- Ying Wang, Dr.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 60 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- De novo and primary Ph/BCR-ABL1 negative acute lymphoblastic leukemia diagnosed by the bone marrow cytomorphology, immunophenotyping, cytogenetics and molecular biology according to WHO classification
- Age: 14 -60 years
- Male or female
- ECOG Performance Status 0-2
- Adequate end organ function as defined by: Total bilirubin ≤ 1.5 x upper limit of normal(ULN); serum alanine aminotransferase (ALT) and serum aspartate aminotransferase (AST) ≤ 2.5 x ULN or ≤5 x ULN if leukemic involvement of the liver is present; Creatinine ≤ 1.5 x ULN; Serum amylase and lipase ≤ 1.5 x ULN; Alkaline phosphatase ≤ 2.5 x ULN unless considered tumor related; normal electrolytes: Potassium ≥ LLN; Magnesium ≥ LLN; Phosphorus ≥ LLN; Cardiac color Doppler ultrasound ejection fraction ≥ 45%;
- Subject has provided written informed consent prior to any screening procedure
Exclusion Criteria:
- Burkitt lymphoma/leukemia
- Acute Leukemia of Ambiguous Lineage
- Female patients who are pregnant or breast feeding
- Uncontrolled active serious infections that could, in the investigator's opinion, potentially interfere with the completion of treatment
- History of pancreatitis
- Poorly controlled diabetes, defined as glycosylated hemoglobin (HbA1c) values of >7.5%. Patients with preexisting, well-controlled diabetes are not excluded
- History of active gastrointestinal bleeding within the last 6 months
- History of arterial/venous thrombosis within the last 6 months
- Known HIV seropositivity
- Any serious psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pediatric-inspired Regimen Combined With Venetoclax
Induction therapy is administered as follows:Vincristine (VCR) 1.4 mg/m2 (maximum dose 2 mg) IV on D1,8,1,5,22; Daunorubicin (DNR) 30 mg/m2/day IV on D1-3; Cyclophosphamide (CTX) 1200 mg/m2 IV on D1,15; Pegaspargase 2500u/m2 IM on D5; Prednisone 1 mg/kg/d PO on D1-14, 0.5 mg/kg/d PO on D15-28; Venetoclax 100 mg PO on D6,200 mg on D7, 400mg on D8-14, All patients underwent bone marrow aspiration on day 14 during induction.
Patients with bone marrow blasts ≥10% on day 14 of induction received 7 additional days of Venetoclax on day 15-22.
Consolidation therapy is a combination of multi-drug pediatric-inspired regimen chemotherapy and Venetoclax.
Maintenance therapy consisted of a monthly VMMP regimen (vincristine, mercaptopurine, methotrexate, prednisone) continuing until 3 years for male and 2.5 years for female patients.
|
Anti-tumor alkaloids
Anthracycline
Alkylating agent
Polyethylene glycol (PEG) conjugated to L-asparaginase
Glucocorticoids
Pyrimidine antimetabolites
Cell cycle-specific antitumor drug
Glucocorticoids
Antifolate antineoplastic drug
Selective inhibitor of B-cell lymphoma 2 (Bcl-2)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
MRD-negative complete remission rate measured by flow cytometry
Time Frame: After induction (4 week)
|
After induction (4 week)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete remission (CR) rate
Time Frame: After 2 cycles of chemotherapy, an expected average of 3 months
|
After 2 cycles of chemotherapy, an expected average of 3 months
|
|
Overall survival (OS)
Time Frame: Up to 5 years post-registration
|
From the date of registration to the date of death resulting from any cause
|
Up to 5 years post-registration
|
Relapse free survival (RFS)
Time Frame: Up to 5 years post-registration
|
From the date of complete remission(CR) until the date of documented relapse or death due to any cause or the last follow-up day
|
Up to 5 years post-registration
|
Disease-free Survival (DFS)
Time Frame: Up to 5 years post-registration
|
From CR1 to relapse, death from any cause or last follow-up
|
Up to 5 years post-registration
|
The rate of adverse events
Time Frame: An expected average of 24 months
|
An expected average of 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 31, 2022
Primary Completion (Anticipated)
December 15, 2024
Study Completion (Anticipated)
December 30, 2027
Study Registration Dates
First Submitted
December 13, 2022
First Submitted That Met QC Criteria
December 13, 2022
First Posted (Actual)
December 21, 2022
Study Record Updates
Last Update Posted (Estimate)
March 3, 2023
Last Update Submitted That Met QC Criteria
March 1, 2023
Last Verified
December 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Respiratory Tract Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Respiration Disorders
- Chromosome Aberrations
- Translocation, Genetic
- Respiratory Aspiration
- Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphoid
- Philadelphia Chromosome
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiviral Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Dermatologic Agents
- Antibiotics, Antineoplastic
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Dexamethasone
- Cyclophosphamide
- Venetoclax
- Prednisone
- Cytarabine
- Methotrexate
- Vincristine
- Daunorubicin
- Mercaptopurine
- Pegaspargase
Other Study ID Numbers
- IIT2022052-EC-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Precursor Cell Lymphoblastic Leukemia-Lymphoma
-
Therapeutic Advances in Childhood Leukemia ConsortiumTerminatedAcute Lymphoblastic Leukemia | Precursor B-Cell Lymphoblastic Leukemia | Precursor T-Cell Lymphoblastic LeukemiaUnited States, Australia
-
Bristol-Myers SquibbCompletedLymphoblastic Leukemia, Acute T-cell | Precursor T-Cell Lymphoblastic LymphomaUnited States, France, Germany
-
Asan Medical CenterTerminatedLymphoblastic Lymphoma | Leukemia, Biphenotypic, Acute | Leukemia, Acute Lymphoblastic | Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Precursor B-Cell Lymphoblastic LeukemiaKorea, Republic of
-
PfizerCompletedLeukemia | Precursor b-Cell Lymphoblastic Leukemia-Lymphoma | ACUTE LYMPHOBLASTIC LEUKEMIAUnited States, Spain, Taiwan, Singapore, India, Hungary, Turkey, Poland
-
Beam Therapeutics Inc.RecruitingLymphoblastic Lymphoma | Lymphoblastic Leukemia | T-Cell Lymphoblastic Leukemia/LymphomaUnited States
-
Wugen, Inc.RecruitingLymphoblastic Lymphoma | T-cell Acute Lymphoblastic LeukemiaUnited States, Australia, Netherlands, France
-
SanofiTerminatedT-cell Type Acute Leukemia-Precursor | T-lymphoblastic Lymphoma/LeukaemiaHungary, United States, Finland, France, Italy, Lithuania, Russian Federation
-
First Affiliated Hospital of Zhejiang UniversityRecruitingCytarabine+Thiotepa + Fludarabine + Busulfan | T Cell Acute Lymphoblastic Leukemia/Lymphoblastic LymphomaChina
-
920th Hospital of Joint Logistics Support Force...WithdrawnT-lymphoblastic Lymphoma | T-cell Acute Lymphoblastic LeukemiaChina
-
BioCryst PharmaceuticalsTerminated
Clinical Trials on Vincristine
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); Spectrum Pharmaceuticals, IncTerminatedVincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaRecurrent Adult Acute Myeloid LeukemiaUnited States
-
ECOG-ACRIN Cancer Research GroupRecruitingRecurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia | Lymphoblasts 5 Percent or More of Bone Marrow Nucleated CellsUnited States
-
Centre Oscar LambretSFCECompleted
-
M.D. Anderson Cancer CenterInex PharmaceuticalsCompletedSoft Tissue Sarcoma | Lymphoma | Leukemia | Osteosarcoma | Wilms' TumorUnited States
-
Nanjing Luye Sike Pharmaceutical Co., Ltd.China Medical University, China; Xijing Hospital; The Second Hospital of Hebei... and other collaboratorsUnknownAdult Acute Lymphoblastic LeukemiaChina
-
Spectrum Pharmaceuticals, IncParexelCompletedAcute Lymphoblastic Leukemia (ALL)United States, Canada, Germany, Israel, United Kingdom
-
Spectrum Pharmaceuticals, IncTerminatedAcute Lymphoblastic Leukemia (ALL)United States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedIntraocular RetinoblastomaUnited States, Canada, Australia, New Zealand, India
-
Dartmouth-Hitchcock Medical CenterTerminatedChronic Lymphocytic Leukemia (CLL)United States
-
Societe Internationale d'Oncologie PediatriqueCompletedPrimary Central Nervous System NeoplasmsFrance, United Kingdom, Italy, Germany, Switzerland, Belgium, Denmark, Norway, Austria, Croatia, Poland, Portugal